| Expression pattern: |
DN |
| Associated gene: |
COL3A1 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits human PASMC phenotypic switching from a contractile to a proliferative synthetic phenotype; inhibits hypoxia-induced PASMC proliferation and migration; attenuates pulmonary vascular remodeling and pulmonary artery fibrosis in SuHx-induced PH. |
| Molecular mechanism: |
circGUCY1A2 binds COL3A1 at the Ser1132 and Ser1145 O-glycosylation sites, reduces COL3A1 O-glycosylation and stability, promotes ubiquitin/proteasome-mediated COL3A1 degradation, affects OPN expression, and thereby inhibits PASMC phenotypic switching in PH. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); fibrosis (inhibits); ubiquitination (promotes); other pathway/process (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; IF (Immunofluorescence); RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Transfection; CCK8; EdU Staining; Wound Healing Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis |
| Clinical significance: |
potential therapeutic target and prognostic indicator for PH |
| Description: |
circGUCY1A2 is downregulated under hypoxic PH-related conditions and acts as an inhibitory regulator of PASMC phenotypic switching. Mechanistically, it binds COL3A1 at Ser1132/Ser1145 O-glycosylation sites, reduces COL3A1 glycosylation and stability, affects OPN expression, and suppresses PASMC proliferation, migration, pulmonary vascular remodeling, and pulmonary artery fibrosis. |
| Confidence score: |
0.8479 |